Latest Boardroom Shifts News

Deep Yellow Limited reports significant progress on its flagship Tumas Project in Namibia, highlighted by promising high-grade uranium discoveries at the S-Bend prospect and steady advancement of infrastructure and engineering works. Meanwhile, leadership changes and a robust cash position set the stage for the company’s next growth phase.

Deterra Royalties announces the resignation of CEO Julian Andrews by year-end, with Non-executive Director Jason Neal stepping in as interim CEO amid a search for a permanent replacement.

Acumentis delivered a 3.4% revenue increase to $58.1 million at its 2025 AGM, highlighting diversification and a positive outlook for FY26 amid easing inflation and expected rate cuts.

King River Resources reports encouraging gold assay results from its Kurundi Project and promising soil geochemical anomalies at Kuiper IOCG targets, underpinning ongoing exploration momentum in the Tennant Creek region.

Michael Hill International reported flat earnings in FY25 amid inflation and subdued demand, while new CEO Jonathan Waecker outlines a strategy focused on innovation, AI integration, and margin recovery heading into FY26.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Atlas Arteria reported a robust 10.9% increase in Q3 2025 toll revenue, driven by strong traffic growth across its global portfolio and strategic toll hikes. The company also appointed Kara Lawrence as CEO of Dulles Greenway, signaling a new leadership phase.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Kingfisher Mining has appointed geologist Chris Bittar as Managing Director, aiming to leverage his expertise to advance its NSW and Western Australian mineral projects.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Wellnex Life Limited announces the resignation of CEO Zack Bozinovski, who will remain with the company until April 2026, while a $2.3 million loan repayment schedule is negotiated.

Tasman Resources has raised $2 million through a two-tranche placement to fund a promising drilling campaign at Parkinson Dam and broaden its project portfolio, alongside appointing a new director to steer its strategic ambitions.